NUVISAN headquarters are located in Neu-Ulm, in the southern part of Germany at the very heart of the DACH region. Our site boasts an in-house clinical pharmacology unit (CPU) with 140 beds offering a wide range of solutions for early clinical trials, including project leadership team, monitoring, medical writing, and CDM/STAT.
Our clinical activities are supported on-site by a wide range of expertise: QC testing, bioanalysis of small and large molecules, cell-based assays, biomarkers, and clinical trial supplies, including GMP manufacturing and packaging services.
Located in the heart of Berlin, the Innovation Campus Berlin (ICB) was acquired by NUVISAN in 2020 as a fully functional pharma R&D unit. ICB brings decades of successful drug discovery and development expertise in a broad indication spectrum, including oncology, as well as women’s and men’s health and cardiovascular diseases.
With all capabilities located under one roof in Berlin, NUVISAN ICB provides fully integrated solutions across the entire discovery value chain, from target identification to preclinical candidates, covering discovery pharmacology, discovery biosciences, screening, translational research, life science chemistry, digital life sciences, DMPK, discovery bioanalysis, and toxicology. A particular strength is the strong foothold working on small molecules, with access to a high-quality compound library. With a staff that is more than 90% scientists and lab professionals, ICB is headed by an experienced leadership team of former pharma research executives.
For complex studies and clinical trials in patients, the Gauting site performs the planning, conduct and evaluation of clinical trials with complex endpoints in healthy subjects or patients from phase I studies (first-in-man studies, safety studies, and pharmacokinetic and pharmacodynamic studies in healthy subjects or patients) to phase II studies (studies of clinical efficacy in patients).
With a special expertise in the respiratory therapeutic area, we have access to cystic fibrosis patients and can perform flow-profile investigations of inhaler devices.
Excellence center for non-clinical in vitro and in vivo DMPK, isotope chemistry and QWBA, discovery and GLP bioanalysis, and metabolite profiling and identification. The site also boasts mass spectrometry with license to handle radioactivity. Our Grafing site includes state-of-the-art animal housing, as well as dedicated equipment for radioactive synthesis.
This site was established by Galderma in 2006 on the French Riviera to become the largest R&D site in the world dedicated to dermatology. The site offers a wide range of solutions, including chemical development (process development and API GMP manufacturing), development of innovative formulations, GMP manufacturing of semisolid products, analytical development and QC, clinical trial supplies (small and large molecules), bioanalysis services, and quality assurance and regulatory affairs services.
Gender Equality Index for the year 2023 based on 2022 data: Total score 93/100.
This includes 79 points out of a maximum possible 85, including:
- gender pay gap indicator: 34/40
- indicator of the gap in the rate of salary increases: 35/35
- indicator of the proportion of employees receiving the highest salaries: 10/10
Index égalité professionnelle entre les femmes et les hommes pour l’année 2023 au titre des données 2022: Résultat total 93/100.
79 points sur un maximum de 85 pouvant être obtenus, dont :
- indicateur écart de rémunération: 34/40
- indicateur écart de taux d’augmentation: 35/35
- indicateur hautes rémunérations: 10/10
With a specialization in pharmaceutical solutions, including GMP-compliant release and stability testing of pharmaceuticals, we offer method development, transfer and validation of methods for a wide range of APIs, and formulations ranging from small-molecule tablet formulations to parenteral therapeutic antibody solutions. Physical testing of primary packaging can also be performed with container closure integrity testing (CCIT) using the following techniques: blue dye, high-voltage leak detection, oxygen and carbon dioxide heaspace gas analyzer, and break loose and glide testing.
With 20 years of experience in oncology drug development in Latin America and well-established affiliate operations, NUVISAN can effectively support clinical management and monitoring for late-phase oncology studies in this region. NUVISAN also offers tailored concepts across all key therapeutic areas, with a strong focus on pivotal phase II/III studies, as well as on late-phase approaches, such as observational studies, for regional and national projects.